Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Allefin** is a Polish fixed-dose topical gel developed and manufactured by Hasco-Lek. Each gram contains diphenhydramine hydrochloride 20 mg, a first-generation H1 antihistamine that suppresses histamine-mediated itch and allergic skin responses, and lidocaine hydrochloride 10 mg, a local anesthetic that blocks voltage-gated sodium channels to provide local analgesia. It is indicated for symptomatic treatment of pruritic contact allergic and inflammatory skin lesions caused by external exposures, including insect and arachnid bites or stings, contact with plants such as nettles or ivy, and jellyfish stings; it is used in adults, adolescents, and children aged 2 years and older. ([rejestrymedyczne.ezdrowie.gov.pl](https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/38703/leaflet))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allefin.